Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

A Phase 2 study testing ACC-001, QS-21 and PBS in people with Alzheimer Disease, run by Pfizer at 10 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug. Read more about this study

Who is it for?: Ages 50 to 85 years
Conditions the study is for: Alzheimer Disease
What is being tested?: ACC-001, QS-21 and PBS
Type of treatment: Vaccines, Injection or infusion
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 40 participants
Where: 10 sitesJapan
Study dates: Dec 2008to Jul 2012
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 50 to 85 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosis of mild to moderate Alzheimer's Disease
Mini Mental Status Exam (MMSE) of 16-26

Who cannot join

Significant Neurological Disease
Major Psychiatric Disorder
Clinically significant systemic illness

Trial locations and contacts

10 sites in 1 country.

City, postcode or hospital

10 sites in 1 country

Japan10 sites

Meitetsu Hospital
Aichi, 451-8511
Ibaraki Prefectural Central Hospital
Ibaraki, 309-1793
Shonan Atsugi Hospital
Kanagawa, 243-8551
Kitasato University East Hospital
Kanagawa, 252-0380
Tazuke Kofukai Medical Research Institute Kitano Hospital
Osaka, Osaka, 530-8480
Suwa Red Cross Hospital
Suwa, Nagano, 392-8510
Osaka Medical College Hospital
Takatsuki, Osaka, 569-8686
Juntendo University Hospital
Tokyo, 113-8431
Juntendo Tokyo Koto Geriatric Medical Center
Tokyo, 136-0075
Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache
Tokyo, 158-8531

Other trials in Japan

About this study

Official title: A Phaseiia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.

Conditions: Alzheimer Disease
Being tested: ACC-001, QS-21, PBS
Keywords: Phase IIa, multiple ascending dose study of ACC-001
Medical subject headings: Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ACC-001Biological
IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
QS-21Other
IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
ACC-001Biological
IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
QS-21Other
IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
PBSOther
IM injection, Day 1, month 3, 6, 9, 12

Study groups in NCT00752232
Study group	Role	What they receive
ACC-001+QS-21	Experimental	Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12 Receives: Biological: ACC-001; Other: QS-21
ACC-001	Experimental	Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12 Receives: Biological: ACC-001
QS-21	Placebo comparator	Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12 Receives: Other: QS-21
PBS	Placebo comparator	Placebo, IM injection, Day 1, month 3, 6, 9, 12 Receives: Other: PBS

What is being measured

The primary outcome is the main question the study is designed to answer.

Incidence of Treatment-emergent Adverse Events (AEs) by Severity
Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)
Measured: Baseline up to 24 months
Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data
Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by investigator.
Measured: Baseline up to 24 months
Number of Participants With Abnormalities in Neurological Examination
Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.
Measured: Baseline up to 24 months

Secondary outcomes (2)

Anti-a-beta IgG Titer at Specified Visits
Geometric mean of anti-a-beta IgG titer from pre-study through Week 104
Measured: Baseline up to 24 months
Anti-a-beta IgM Titer at Specified Visits
Geometric mean of anti-a-beta IgM titer from pre-study through Week 104
Measured: Baseline up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Dec 2008Jul 2012

First posted15 Sep 2008 (estimated)
Study startDec 2008
Primary completionJul 2012
Study completionJul 2012

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
More trials run by PfizerThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Factorial
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 40 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00752232
Sponsor's protocol ID: 3134K1-2202
Other IDs: B2571006
Status last verified: Nov 2015
First submitted: 11 Sep 2008
Last updated: 1 Jan 2016
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Arai H, Suzuki H, Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr Alzheimer Res. 2015;12(3):242-54. doi: 10.2174/1567205012666150302154121.
PubMed 25731629

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease

All Alzheimer Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 1 Jan 2016. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phaseiia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.
ClinicalTrials.gov ID: NCT00752232
Acronym / sponsor ID: 3134K1-2202
Conditions: Alzheimer Disease
Keywords: Phase IIa, multiple ascending dose study of ACC-001
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 40 participants (actual)
Lead sponsor: PfizerIndustry (pharma, biotech, devices)
Collaborators: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Study start: Dec 2008
Primary completion: Jul 2012 (actual)
Study completion: Jul 2012 (actual)
First posted: 15 Sep 2008 (estimated)
Results: Posted 1 Jan 2016

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Factorial
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
ACC-001+QS-21	Experimental	Biological: ACC-001, Other: QS-21Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
ACC-001	Experimental	Biological: ACC-001Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
QS-21	Placebo comparator	Other: QS-21Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
PBS	Placebo comparator	Other: PBSPlacebo, IM injection, Day 1, month 3, 6, 9, 12

Who may qualify

Ages: 50 to 85 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

Diagnosis of mild to moderate Alzheimer's Disease
Mini Mental Status Exam (MMSE) of 16-26

Key exclusion criteria (3 listed)

Significant Neurological Disease
Major Psychiatric Disorder
Clinically significant systemic illness

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ACC-001IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12	Biological	ACC-001+QS-21
QS-21IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12	Other	ACC-001+QS-21
ACC-001IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12	Biological	ACC-001
QS-21IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12	Other	QS-21
PBSIM injection, Day 1, month 3, 6, 9, 12	Other	PBS

Primary outcome

Incidence of Treatment-emergent Adverse Events (AEs) by Severity
Time frame: Baseline up to 24 months
Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)
Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data
Time frame: Baseline up to 24 months
Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by investigator.
Number of Participants With Abnormalities in Neurological Examination
Time frame: Baseline up to 24 months
Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.

2 secondary outcomes

Anti-a-beta IgG Titer at Specified Visits
Time frame: Baseline up to 24 months
Anti-a-beta IgM Titer at Specified Visits
Time frame: Baseline up to 24 months

Results and safety

Results posted to the registry on 1 Jan 2016, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
ACC-001 3 Micrograms +QS-21	6	4
ACC-001 10 Micrograms	6	6
ACC-001 10 Micrograms + QS-21	6	5
ACC-001 30 Micrograms	6	5
ACC-001 30 Micrograms +QS-21	6	3
QS-21	6	5
Phosphate Buffered Saline (PBS)	4	4

Primary outcome: Incidence of Treatment-emergent Adverse Events (AEs) by Severity

Time frame: Baseline up to 24 months. Number. Unit: Participants

Measure	ACC-001 3 Micrograms +QS-21 n = 6	ACC-001 10 Micrograms n = 6	ACC-001 10 Micrograms + QS-21 n = 6	ACC-001 30 Micrograms n = 6	ACC-001 30 Micrograms +QS-21 n = 6	QS-21 n = 6	Phosphate Buffered Saline (PBS) n = 4
Mild	5	6	4	5	3	6	3
Moderate	0	0	0	1	2	0	0
Severe	1	0	0	0	0	0	0

Population analysed: The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.

Primary outcome: Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data

Time frame: Baseline up to 24 months. Number. Unit: Participants

Measure	ACC-001 3 Micrograms +QS-21 n = 6	ACC-001 10 Micrograms n = 6	ACC-001 10 Micrograms + QS-21 n = 6	ACC-001 30 Micrograms n = 6	ACC-001 30 Micrograms +QS-21 n = 6	QS-21 n = 6	Phosphate Buffered Saline (PBS) n = 4
Abnormal-inconsistent with AD	0	0	0	0	0	1	0
Abnormal-consistent with AD	6	6	6	6	6	5	4

Population analysed: The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.

Primary outcome: Number of Participants With Abnormalities in Neurological Examination

Time frame: Baseline up to 24 months. Number. Unit: Participants

Measure	ACC-001 3 Micrograms +QS-21 n = 6	ACC-001 10 Micrograms + QS-21 n = 6
Total	2	1
Mental Status	1	1
Speech	1	0
Cranial Nerves	0	0
Visual field	0	0
Sensory	0	0
Motor	0	0
Coordination	0	0

Population analysed: The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.

2 secondary outcomes are reported in the full results.

Adverse events

Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
ACC-001 3 Micrograms +QS-21	1 of 6 (16.7%)	6 of 6 (100%)	Not reported
ACC-001 10 Micrograms	0 of 6 (0%)	6 of 6 (100%)	Not reported
ACC-001 10 Micrograms + QS-21	0 of 6 (0%)	4 of 6 (66.7%)	Not reported
ACC-001 30 Micrograms	0 of 6 (0%)	6 of 6 (100%)	Not reported
ACC-001 30 Micrograms + QS-21	1 of 6 (16.7%)	5 of 6 (83.3%)	Not reported
QS-21	0 of 6 (0%)	6 of 6 (100%)	Not reported
Phosphate Buffered Saline (PBS)	0 of 4 (0%)	3 of 4 (75%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 1 Jan 2016.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 25731629Arai H, Suzuki H, Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr Alzheimer Res. 2015;12(3):242-54. doi: 10.2174/1567205012666150302154121.
To obtain contact information for a study center near you, click here.Link provided by the sponsor.

Related trials for Alzheimer Disease

RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Pfizer CT.gov Call Center study director

Pfizer

10 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ACC-001, QS-21 and PBS in people with Alzheimer Disease, run by Pfizer at 10 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jan 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Treatment-emergent Adverse Events (AEs) by Severity (time frame: Baseline up to 24 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00752232, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jan 2016.